DEPO-MEDROL J Code: J1040

Drug & Product Overview

HCPCS Descriptor Injection, methylprednisolone acetate, 80 mg

HCPCS Added Date January 1, 1982

Manufacturer Multiple Manufacturers

Route of Administration Intra-Arterial, Intra-Articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue

Generic Status HCPCS Discontinued

Dosage Type Single-Dose, Multi-Dose

Dosage Form Injection, Suspension

About DEPO-MEDROL

Depo-medrol is a medication aligned to the HCPCS J Code: J1040 for billing, pricing, and reimbursement purposes in the United States. Classified under Immunology, it is administered via the intra-arterial, intra-articular, intralesional, intramuscular, intrasynovial, or soft tissue routes and manufactured by multiple companies.

Manufacturers, reach out to us to add more information.

NDC Code Information

15 NDC packages are crosswalked to J1040. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	DEPO-MEDROL
	DEPO-MEDROL
	DEPO-MEDROL
	DEPO-MEDROL

Login to view 15 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

DEPO-MEDROL CPT Administration Codes

CPT Code	Description
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

CMS does not include Depo-medrol (J1040) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J1040. Wastage billing guide →

DEPO-MEDROL Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute Severe Dermatitis due to Poison Ivy Acute nonspecific tenosynovitis Acute severe dermatitis due to poison ivy Adrenogenital Syndrome Adrenogenital syndrome Allergic states (asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions) Alopecia areata Asthma Bursitis Bursitis, tenosynovitis, tendinitis, epicondylitis, and ganglia Cerebral edema associated with primary or metastatic brain tumor or craniotomy Chronic Contact Dermatitis Chronic contact dermatitis Conditions requiring systemic corticosteroid therapy Congenital adrenal hyperplasia (adrenogenital syndrome) Cystic tumors of an aponeurosis or tendon (ganglia) Dermatologic Conditions (intralesional) Dermatologic Lesions (systemic IM) Dermatologic Lesions (systemic corticoid therapy) Dermatologic Lesions (systemic) Dermatologic conditions (intralesional) Dermatologic conditions (local) Dermatologic diseases (bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme) Dermatologic diseases (systemic corticoid therapy) Dermatologic lesions Dermatologic lesions (intralesional) Dermatologic lesions (systemic IM) Dermatologic lesions (systemic corticoid therapy) Discoid lupus erythematosus Endocrine disorders (adrenocortical insufficiency, hypercalcemia associated with cancer, nonsuppurative thyroiditis) Epicondylitis Ganglion, Tendinitis, Epicondylitis Granuloma annulare Hematologic disorders (autoimmune hemolytic anemia, Diamond Blackfan anemia, pure red cell aplasia, secondary thrombocytopenia) Idiopathic nephrotic syndrome or nephrotic syndrome due to lupus erythematosus Keloids Leukemias and lymphomas Lichen planus Lichen simplex chronicus (neurodermatitis) Multiple Indications (IM systemic — general) Multiple Indications (IM systemic — oral substitute weekly) Multiple Indications (IM systemic — oral substitute) Multiple Indications (IM systemic — pediatric) Multiple Indications (systemic IM — general) Multiple indications (general systemic IM use) Multiple indications (systemic IM therapy) — general Multiple indications (systemic IM therapy) — pediatric Multiple indications — systemic IM (general) Multiple systemic conditions (general IM use) Necrobiosis lipoidica diabeticorum Ophthalmic diseases (sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions) Osteoarthritis Psoriatic plaques Regional enteritis and ulcerative colitis Respiratory diseases (berylliosis, pulmonary tuberculosis, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis) Rheumatic disorders (acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, dermatomyositis, polymyositis, systemic lupus erythematosus) Rheumatoid Arthritis Rheumatoid Arthritis (systemic IM maintenance) Rheumatoid Arthritis and Osteoarthritis Rheumatoid arthritis Rheumatoid arthritis (systemic IM) Rheumatoid arthritis (systemic) Rheumatoid arthritis and osteoarthritis Seborrheic Dermatitis Seborrheic dermatitis Systemic conditions (general IM use) Tendinitis, Tenosynovitis, Epicondylitis, Ganglion Tendinitis, tenosynovitis, epicondylitis, ganglion of tendon sheath Trichinosis with neurologic or myocardial involvement Tuberculous meningitis with subarachnoid block dental and oral surgery procedures local or regional anesthesia or analgesia obstetrical procedures

Show all 73 conditions Show fewer

Drug Class

Corticosteroid Hormone Receptor Agonists [MoA]Corticosteroid [EPC]

Frequently Asked Questions

Is there an available Depo-Medrol billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for DEPO-MEDROL.

Are there any available Depo-Medrol patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for DEPO-MEDROL.

Where can I find Depo-Medrol prescribing information?

DEPO-MEDROL prescribing information can be found at the link below: Visit Here →

Where can I find Depo-Medrol side effect information?

Information regarding DEPO-MEDROL's side effects can be found at MedlinePlus Visit Here →

Does billing DEPO-MEDROL require JZ/JW wastage modifiers?

CMS does not include DEPO-MEDROL (J1040) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J1040. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.